Dr. Dale L. Boger Honored With 2014 AACR Award for Outstanding Achievement in Chemistry in Cancer Research
SAN DIEGO — The American Association for Cancer Research (AACR) will recognize Dale L. Boger, Ph.D., Richard and Alice Cramer professor of chemistry and chair of the Department of Chemistry and the Skaggs Institute for Cancer Research at the Scripps Research Institute, La Jolla, Calif., with the Eighth Annual AACR Award for Outstanding Achievement in Chemistry in Cancer Research at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.
The AACR and its Chemistry in Cancer Research Working Group established the AACR Award for Outstanding Achievement in Chemistry in Cancer Research in 2007 to recognize the importance of chemistry to advancements in cancer research. The award is given for outstanding, novel, and significant chemistry research, which has led to important contributions to the fields of basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer, or the treatment of patients with cancer.
He will present his lecture, “Uniquely Effective Synthetic Analogs of the Complex Antitumor Natural Products Vinblastine and the Duocarmycins,” Tuesday, April 8, 3 p.m. PT, in Ballroom 20D in the San Diego Convention Center.
Boger is being recognized for his important research in combining novel synthetic methodology to develop natural products and designing second-generation synthetic compounds as potent anticancer agents. His studies have led to the elucidation of the mechanisms by which several anticancer agents interact with the DNA, and the creation of unique drug design paradigms.
His accomplishments include the synthesis of CC-1065, a naturally occurring agent with exceptional antitumor properties, which provided a template for the development of many new anticancer compounds. He continues to design synthetic analogs with duocarmycin O-aminophenol prodrugs, and analogs of other anticancer compounds including bleomycin, camptothecin, and vinca alkaloids. His contributions to the field also include the synthesis of comprehensive libraries for modulating protein-protein and protein-DNA interactions, and libraries for minor groove DNA-binding studies. He also developed rapid, high-throughput screens for determining relative DNA-binding affinity and DNA-binding sequence selectivity of the libraries, which led to identifying novel DNA-binding agents.
“I am thrilled and especially honored to have our work recognized by such a prestigious award by the American Association for Cancer Research,” said Boger, who is also co-founder of Abide Therapeutics and founding editor and current editor-in-chief of Bioorganic and Medicinal Chemistry Letters.
Boger has received numerous honors throughout his career, including multiple awards from the American Chemical Society (ACS), the Adrien Albert Medal from the Royal Society of Chemistry, and the Paul Janssen Prize for Creativity in Organic Synthesis.
He is a fellow of the ACS, the Royal Society of Chemistry, the American Association for the Advancement of Science, an honorary member of the Lund Chemical Society of Sweden, as well as a member of the AACR, the ACS, and the American Association for the Advancement of Science, among others.
Boger received his bachelor’s degree from the University of Kansas in Lawrence, and his doctorate in organic chemistry from Harvard University in Cambridge, Mass. Prior to his position at the Scripps Research Institute, Boger was a faculty member at the University of Kansas (1979-1985) and Purdue University in West Lafayette, Ind. (1985-1990). Since 1998, he has also been adjunct professor of medicinal chemistry at the University of Kansas.
The AACR Award for Outstanding Achievement in Chemistry in Cancer Research is generously supported by Ash Stevens, Inc.